Dinitrophenyl-modified autologous tumor-associated antigens presented in major histocompatibility complex (DNP-modified TAA-MHC)

DNP-modified autologous tumor-associated antigens presented in MHC complexes are the primary targets of hapten-based cancer immunotherapies (Berd et al., 1986, PubMed: 3522837). This approach involves the chemical conjugation of dinitrophenyl (DNP), a highly immunogenic hapten, to a patient's own (autologous) tumor cells or extracted antigens. When these modified antigens are processed and presented by Major Histocompatibility Complex (MHC) molecules, they appear "foreign" to the immune system, thereby breaking immunological tolerance to the tumor (Manne et al., 2002, PubMed: 12124322). This modification stimulates a potent cellular immune response, characterized by the recruitment and activation of CD4+ and CD8+ T cells. The resulting immune response is directed not only against the DNP-modified antigens but also against the unmodified tumor antigens through a process known as epitope spreading (Berd et al., 2004, PubMed: 15313910). Historically, this target has been utilized in the development of autologous vaccines, such as M-Vax, for the treatment of metastatic melanoma and ovarian cancer (NCI Drug Dictionary).

Other names

DNP-modified tumor antigensDNP-haptenized tumor antigensDNP-modified autologous tumor cellsDNP-TAA-MHC complex

Haptenization of tumor-associated antigens with dinitrophenyl (DNP) increases their immunogenicity, facilitating the bypass of immune tolerance and promoting the activation of cytotoxic T lymphocytes (CTLs) and helper T cells against the tumor cells (Berd et al., 1991, PubMed: 1829052).